Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) Shares Outstanding (Diluted Average): 2021-2025

Historic Shares Outstanding (Diluted Average) for Tango Therapeutics (TNGX) over the last 4 years, with Jun 2025 value amounting to $110.5 million.

  • Tango Therapeutics' Shares Outstanding (Diluted Average) rose 1.70% to $110.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $110.5 million, marking a year-over-year increase of 1.70%. This contributed to the annual value of $109.2 million for FY2024, which is 15.50% up from last year.
  • Tango Therapeutics' Shares Outstanding (Diluted Average) amounted to $110.5 million in Q2 2025, which was up 0.22% from $110.3 million recorded in Q1 2025.
  • In the past 5 years, Tango Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $110.5 million in Q2 2025 and a low of $48.5 million during Q2 2021.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $102.4 million, with a median of $108.4 million in 2024.
  • Data for Tango Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY spiked of 81.02% (in 2022) over the last 5 years.
  • Over the past 5 years, Tango Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $62.1 million in 2021, then skyrocketed by 41.40% to $87.8 million in 2022, then climbed by 7.69% to $94.6 million in 2023, then grew by 15.50% to $109.2 million in 2024, then climbed by 1.70% to $110.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $110.5 million in Q2 2025, compared to $110.3 million in Q1 2025 and $109.2 million in Q4 2024.